Table 1.
Baseline characteristics of study cohort
| Number | LN class | Current treatment | Previous CYC (total dose, g) | Previous RTX (total cycle number) | Protein: creatinine ratioa (mg/mmol) | SLEDAI | BILAG/ renal | SLE (LN) duration (years) |
|---|---|---|---|---|---|---|---|---|
| Active | ||||||||
| 1 | III (A/C) | MMF, HCQ | 0 | 0 | 290 | 8 | 13/A | 0 (0) |
| 2 | IV-S (A) | MMF, HCQ, Pred | 0 | 0 | 223 | 19 | 45/A | 8 (7) |
| 3 | III (A) | HCQ | 0 | 0 | 289 | 13 | 23/A | 0 (0) |
| 4 | V + III (A) | MMF, HCQ, Pred | 0 | 1 | 604 | 18 | 26/B | 1 (1) |
| 5 | V + III (A/C) | MMF, HCQ, Pred | 0 | 0 | 77 | 8 | 17/B | 1 (0) |
| 6 | V | MMF, HCQ, Pred | 0 | 1 | 270 | 8 | 8/B | 8 (8) |
| 7 | V + III (C) | MMF, HCQ | 0 | 1 | 732 | 6 | 8/B | 5 (4) |
| 8 | III (C) | MMF, HCQ, Pred | 3 | 1 | 91 | 8 | 8/B | 12 (10) |
| 9 | V | MMF, HCQ, Pred | 6 | 1 | 134 | 12 | 13/A | 30 (30) |
| 10 | V + III (A) | MMF, HCQ | 0 | 0 | 2010 | 7 | 34/A | 0 (0) |
| 11 | IV-S (A/C) | MMF, HCQ, Pred | 0 | 0 | 161 | 13 | 31/B | 6 (0) |
| 12 | III (A/C) | HCQ, Pred, i.v.MP×3 | 0 | 0 | 83 | 17 | 15/C | 8 (0) |
| 13 | V + IV-S (A/C) | AZA, Pred | 6 | 1 | 1236 | 10 | 13/A | 6 (5) |
| 14 | IV-G (A) | MTX, HCQ, Pred, i.m.MP×1 | 0 | 1 | 211 | 13 | 30/B | 3 (3) |
| 15 | V + IV-G (A/C) | MMF, Pred | 3 | 0 | 272 | 8 | 12/A | 17 (17) |
| 16 | V + IV-G (C) | MMF, HCQ | 0 | 1 | 398 | 4 | 12/A | 7 (7) |
| 17 | IV−G (C) | HCQ, Pred | 0 | 0 | 161 | 4 | 14/A | 25 (24) |
| 18 | V | MMF | 3 | 0 | 294 | 8 | 12/A | 17 (13) |
| 19 | III (A) | MMF, HCQ | 3 | 1 | 229 | 8 | 13/A | 18 (12) |
| Inactive | ||||||||
| 20 | IV | AZA, Pred | 0 | 0 | <20 | 0 | 0/D | 35 (35) |
| 21 | IV | Pred | 3 | 0 | <20 | 0 | 0/D | 28 (26) |
| 22 | V + III (C) | MMF, HCQ | 0 | 1 | <20 | 0 | 0/D | 29 (28) |
| 23 | V | MMF | 0 | 1 | <20 | 0 | 0/D | 11 (10) |
| 24 | III (A) | AZA, HCQ | 0 | 0 | <20 | 4 | 0/D | 15 (15) |
| 25 | III | HCQ | 0 | 0 | <20 | 2 | 1/D | 10 (10) |
| 26 | IV | HCQ | 3 | 1 | <20 | 0 | 0/D | 4 (4) |
| 27 | V | AZA, HCQ | 0 | 0 | <20 | 2 | 1/D | 30 (25) |
| 28 | III | AZA, HCQ | 0 | 1 | <20 | 3 | 1/D | 7 (7) |
| 29 | III | None | 0 | 1 | <20 | 2 | 2/D | 8 (8) |
| 30 | IV-G (A) | AZA, HCQ | 0 | 3 | <20 | 6 | 2/D | 11 (7) |
CYC and RTX refer to treatments given at least 6 months before this study. LN duration was calculated from the time of the first renal biopsy.
a
The protein:creatinine ratio normal range is <20 mg/nmol. MP: methylprednisolone; Pred: prednisolone; RTX: rituximab.